Last reviewed · How we verify
NCT07120815: MET-PCOS
Optimizing Metformin Use in Polycystic Ovary Syndrome
Phase 3 trial testing Metformin 1500 mg daily in Polycystic Ovary Syndrome (PCOS) in 184 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | Helsinki University Central Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 184 |
| Start date | 1 September 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across Finland |
Drugs / interventions tested
- Metformin 1500 mg daily — full drug profile →
- Metformin 2250 mg daily — full drug profile →
Conditions studied
- Polycystic Ovary Syndrome (PCOS) — all drugs for Polycystic Ovary Syndrome (PCOS) →
Sponsor
Helsinki University Central Hospital
Who can join
Adults 18 to 37, female only, with Polycystic Ovary Syndrome (PCOS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if a metformin dose of 1500 mg or 2250 mg per day is better to treat polycystic ovary syndrome (PCOS) in adults. It will also learn about the adverse effects of metformin. The trial aims to evaluate which metformin dose is better for: 1. improving biochemical and clinical outcomes 2. gastrointestinal side-effects 3. mental health and quality of life Participants will: * Be randomized to take metformin at a dose of either 1500mg or 2250mg every day for 6 months * Visit the clinic three times during the trial for checkups and tests * Answer questionnaires on menstrual cyclicity, mental health, quality of life and side-effects
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07120815
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Metformin 1500 mg daily
Trials testing the same drug.
- NCT07323589 — Impact of Myo-Inositol Alone vs Myo-Inositol Plus Metformin on Conception, Adherence, and Tolerability in PCOS · Phase 3 · completed
Other recruiting trials for Polycystic Ovary Syndrome (PCOS)
Currently open trials in the same condition.
- NCT07298564 — Effect of Magnesium and Levocarnitine on Metabolic and Clinical Outcomes in Women With Polycystic Ovarian Syndrome (PCOS · NA · recruiting
- NCT07394530 — Comparison of IVF Outcomes Between PPOS and Antagonist Protocols in Women With PCOS · NA · recruiting
- NCT07371364 — Mobile Application for Women With Polycystic Ovary Syndrome · NA · active not recruiting
- NCT07242131 — Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS · NA · recruiting
- NCT07171970 — IVM - Fresh ET (THE SAIGON PROTOCOL) Versus IVF - FET in PCOS Women · NA · recruiting
Other Helsinki University Central Hospital trials
Trials by the same sponsor.
- NCT07423637 — The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectivene · NA · not yet recruiting
- NCT07462559 — KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study · Phase 1 · not yet recruiting
- NCT07458984 — FMT Capsules for rCDI · Phase 3 · not yet recruiting
- NCT07001423 — ChOlecystectomy aFter successFul Endoscopic Common Bile Duct Stone Extraction in Elderly · NA · recruiting
- NCT07155629 — Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07120815 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Helsinki University Central Hospital
- Last refreshed: 13 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07120815.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing